HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BIOSTAR PHARM-B

3.700

+0.2507.25%

Volume:17.60K

Turnover:61.64K

Market Cap:1.35B

PE:-9.07

High:3.700

Open:3.500

Low:3.500

Close:3.450

52wk High:19.000

52wk Low:2.400

Shares:364.59M

HK Float Shares:216.72M

Volume Ratio:0.31

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.408

ROE:-18.99%

ROA:-12.47%

PB:1.60

PE(LYR):-9.07

PS:22.36

Loading ...

Overview Company News Filings

Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares

Beijing Biostar Pharmaceuticals (02563) Announces January 2026 Registered Share Capital Update

Bulletin Express

BIOSTAR PHARM-B (02563): First Patient Dosed in U.S. Pivotal Clinical Study of Utidelone for Breast Cancer Brain Metastasis

Biostar Pharma Doses First Patient in Pivotal US Trial of Utidelone for HER2-Negative Breast Cancer Brain Metastases

Breaking the "Untreatable": Biostar Pharma's Utd1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

THOMSON REUTERS

BIOSTAR PHARM-B (02563): Court Approves Company's Application to Appoint Receiver for Sub-Fund; Company Contacts Receiver to Advance Process

Beijing Biostar Pharmaceuticals (02563) Announces November 2025 Monthly Return on Securities Movements

Bulletin Express

BIOSTAR PHARM-B (02563): Legal Counsel Issues Statutory Demand for Debt Repayment to LFM Oversea Investment Limited

Beijing Biostar Pharmaceuticals (2563) Issues Supplemental Announcement for 2024 Annual Report

Bulletin Express

Beijing Biostar Pharmaceuticals (02563) Publishes Monthly Return for October 2025

Bulletin Express

HK Stock Movement | BIOSTAR PHARM-B (02563) Plunges Over 37% as Major Share Unlock Hits Post One-Year Listing

BIOSTAR PHARM-B (02563) Shareholders Deposit Shares with Huatai Hong Kong Worth HK$125 Million

FDA Grants Orphan Drug Designation to Biostar Pharma’s Utidelone for Treatment of Pancreatic Cancer

Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers

Biostar Pharma Successively Achieved First Patient Dosing for Two Phase Ii/Iii Multiregional Clinical Trials of Utidelone Capsule (Utd2)

THOMSON REUTERS

BIOSTAR PHARM-B (02563) Reports Interim Results with Net Loss of RMB 54.04 Million, Narrowing 23.41% Year-on-Year

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02563/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02563","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02563\",,,,,undefined,":{"symbol":"02563","market":"HK","secType":"STK","nameCN":"BIOSTAR PHARM-B","latestPrice":3.7,"timestamp":1770364220511,"preClose":3.45,"halted":0,"volume":17600,"delay":0,"changeRate":0.07246376811594203,"floatShares":216720857,"shares":364588000,"eps":-0.4079,"marketStatus":"Market Closed","change":0.25,"latestTime":"02-06 15:50:20","open":3.5,"high":3.7,"low":3.5,"amount":61640,"amplitude":0.057971,"askPrice":3.7,"askSize":1800,"bidPrice":3.5,"bidSize":12600,"shortable":0,"etf":0,"ttmEps":-0.387594,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"listingDate":1730304000000,"exchange":"SEHK","adjPreClose":3.45,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0.3147353370388108,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02563\",,,,,undefined,":{"symbol":"02563","floatShares":216720857,"roa":"-12.47%","roe":"-18.99%","lyrEps":-0.4079,"volumeRatio":0.3147353370388108,"shares":364588000,"dividePrice":0,"high":3.7,"amplitude":0.057971,"preClose":3.45,"low":3.5,"week52Low":2.4,"pbRate":"1.60","psRate":"22.36","week52High":19,"institutionHeld":0,"latestPrice":3.7,"committee":0.75,"eps":-0.4079,"divideRate":0,"volume":17600,"delay":0,"ttmEps":-0.387594,"open":3.5,"prevYearClose":4.89,"prevWeekClose":3.55,"prevMonthClose":3.55,"prevQuarterClose":4.89,"fiveDayClose":3.55,"twentyDayClose":3.3,"sixtyDayClose":3.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02563\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02563","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null},{"date":"2025-06-30","symbol":"02563","type":"earning","reportTimeType":"pre","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1751247000000,"name":null,"time":"Pre-Market","dateTimestamp":1751212800000,"actualEps":null},{"date":"2025-03-31","symbol":"02563","type":"earning","reportTimeType":"pre","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743384600000,"name":null,"time":"Pre-Market","dateTimestamp":1743350400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02563\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02563\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1734364800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02563\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02563","date":"2026-02-06","current":-9.546071,"percent":0.818471,"low":-63.892303,"twenty":-28.65347,"median":-10.858762,"eighty":-5.701677,"high":-4.541142,"avg":-17.577872,"sd":15.605224,"marketCap":801867170},"quantilePoints":[{"date":"2024-11-01","current":-45.939002,"twenty":-42.207558,"median":-36.610392,"eighty":-34.727382,"marketCap":9515746800},{"date":"2024-11-08","current":-50.657086,"twenty":-48.301262,"median":-46.125418,"eighty":-40.341836,"marketCap":10445446200},{"date":"2024-11-15","current":-51.735366,"twenty":-51.259815,"median":-49.659484,"eighty":-46.008352,"marketCap":10554822600},{"date":"2024-11-22","current":-51.670488,"twenty":-51.75324,"median":-50.936861,"eighty":-46.12281,"marketCap":10536593200},{"date":"2024-11-29","current":-50.005514,"twenty":-51.751568,"median":-51.216637,"eighty":-46.188646,"marketCap":10190234600},{"date":"2024-12-06","current":-53.261904,"twenty":-52.309165,"median":-51.551619,"eighty":-47.62215,"marketCap":10828263600},{"date":"2024-12-13","current":-56.152393,"twenty":-53.128108,"median":-51.673125,"eighty":-49.762114,"marketCap":11393375000},{"date":"2024-12-20","current":-57.66573,"twenty":-54.870186,"median":-51.763763,"eighty":-49.951841,"marketCap":11648586600},{"date":"2024-12-27","current":-56.987991,"twenty":-56.152393,"median":-51.943964,"eighty":-50.005514,"marketCap":11502751400},{"date":"2025-01-03","current":-29.160861,"twenty":-55.458441,"median":-51.76237,"eighty":-46.238834,"marketCap":5891742080},{"date":"2025-01-10","current":-29.88764,"twenty":-55.141356,"median":-51.671807,"eighty":-37.690323,"marketCap":6015702000},{"date":"2025-01-17","current":-26.098924,"twenty":-54.634915,"median":-51.456455,"eighty":-29.807432,"marketCap":5257358960},{"date":"2025-01-24","current":-31.83595,"twenty":-54.024096,"median":-50.936861,"eighty":-29.486496,"marketCap":6453207600},{"date":"2025-01-28","current":-29.272366,"twenty":-53.898416,"median":-50.551705,"eighty":-29.486183,"marketCap":5964659680},{"date":"2025-02-07","current":-27.891403,"twenty":-53.763486,"median":-49.916059,"eighty":-28.779902,"marketCap":5651114000},{"date":"2025-02-14","current":-27.724819,"twenty":-53.195006,"median":-46.201193,"eighty":-28.045447,"marketCap":5614655200},{"date":"2025-02-21","current":-31.716408,"twenty":-52.922578,"median":-45.939002,"eighty":-28.200859,"marketCap":6445915840},{"date":"2025-02-28","current":-28.761543,"twenty":-52.84984,"median":-36.099768,"eighty":-28.259952,"marketCap":5826116240},{"date":"2025-03-07","current":-27.678496,"twenty":-52.618251,"median":-32.29046,"eighty":-28.259952,"marketCap":5629238720},{"date":"2025-03-14","current":-19.855324,"twenty":-52.427717,"median":-31.776179,"eighty":-27.893524,"marketCap":4039635040},{"date":"2025-03-21","current":-15.488933,"twenty":-51.9516,"median":-30.932826,"eighty":-27.594014,"marketCap":3150040320},{"date":"2025-03-28","current":-9.592432,"twenty":-51.908202,"median":-29.673915,"eighty":-27.348197,"marketCap":1946899920},{"date":"2025-04-03","current":-7.937518,"twenty":-51.765156,"median":-29.469494,"eighty":-26.098924,"marketCap":1607833080},{"date":"2025-04-11","current":-7.990601,"twenty":-51.76237,"median":-29.160861,"eighty":-21.966366,"marketCap":1607833080},{"date":"2025-04-17","current":-7.971477,"twenty":-51.740767,"median":-28.859539,"eighty":-19.722121,"marketCap":1607833080},{"date":"2025-04-25","current":-7.964599,"twenty":-51.698021,"median":-28.761543,"eighty":-16.327761,"marketCap":1607833080},{"date":"2025-05-02","current":-7.947706,"twenty":-51.67207,"median":-28.684662,"eighty":-12.879685,"marketCap":1607833080},{"date":"2025-05-09","current":-7.892301,"twenty":-51.665747,"median":-28.653449,"eighty":-9.667878,"marketCap":1607833080},{"date":"2025-05-16","current":-7.828344,"twenty":-51.608717,"median":-28.420136,"eighty":-7.99153,"marketCap":1607833080},{"date":"2025-05-23","current":-7.804998,"twenty":-51.422884,"median":-28.295023,"eighty":-7.977687,"marketCap":1607833080},{"date":"2025-05-30","current":-7.770834,"twenty":-51.274208,"median":-28.099009,"eighty":-7.965975,"marketCap":1607833080},{"date":"2025-06-06","current":-7.751059,"twenty":-51.104727,"median":-27.891403,"eighty":-7.948076,"marketCap":1607833080},{"date":"2025-06-13","current":-7.747995,"twenty":-50.614934,"median":-27.692071,"eighty":-7.919515,"marketCap":1607833080},{"date":"2025-06-20","current":-7.763212,"twenty":-50.358163,"median":-27.513301,"eighty":-7.892411,"marketCap":1607833080},{"date":"2025-06-27","current":-7.741532,"twenty":-49.987623,"median":-27.370929,"eighty":-7.828813,"marketCap":1607833080},{"date":"2025-07-04","current":-11.83634,"twenty":-49.916059,"median":-26.913642,"eighty":-7.828344,"marketCap":1863799370},{"date":"2025-07-11","current":-10.622116,"twenty":-49.659484,"median":-25.451597,"eighty":-7.830688,"marketCap":1670917807},{"date":"2025-07-18","current":-10.713174,"twenty":-46.263928,"median":-22.166181,"eighty":-7.835505,"marketCap":1683921058},{"date":"2025-07-25","current":-11.004065,"twenty":-46.138458,"median":-20.500443,"eighty":-7.892301,"marketCap":1735934064},{"date":"2025-08-01","current":-10.726899,"twenty":-46.112378,"median":-18.6504,"eighty":-7.892301,"marketCap":1681753850},{"date":"2025-08-08","current":-11.168953,"twenty":-45.939002,"median":-15.488933,"eighty":-7.892849,"marketCap":1755438941},{"date":"2025-08-15","current":-11.738095,"twenty":-37.960306,"median":-13.174334,"eighty":-7.893093,"marketCap":1842127284},{"date":"2025-08-22","current":-12.467667,"twenty":-36.610392,"median":-12.190608,"eighty":-7.916058,"marketCap":1950487713},{"date":"2025-08-29","current":-11.994815,"twenty":-35.589144,"median":-12.330873,"eighty":-7.919087,"marketCap":1885471455},{"date":"2025-09-05","current":-13.970683,"twenty":-33.472042,"median":-12.571701,"eighty":-7.921226,"marketCap":1941818878},{"date":"2025-09-12","current":-13.494215,"twenty":-32.29046,"median":-13.141338,"eighty":-7.937518,"marketCap":1878969830},{"date":"2025-09-19","current":-13.239018,"twenty":-32.065299,"median":-13.33247,"eighty":-7.944288,"marketCap":1842127284},{"date":"2025-09-26","current":-13.445231,"twenty":-31.83595,"median":-13.275502,"eighty":-7.947706,"marketCap":1865966578},{"date":"2025-10-03","current":-13.148382,"twenty":-31.740316,"median":-13.293416,"eighty":-7.949184,"marketCap":1829124033},{"date":"2025-10-10","current":-11.950662,"twenty":-31.35646,"median":-13.24589,"eighty":-7.956191,"marketCap":1660081764},{"date":"2025-10-17","current":-9.930211,"twenty":-31.006293,"median":-13.148382,"eighty":-7.963006,"marketCap":1378344650},{"date":"2025-10-24","current":-7.991227,"twenty":-30.305714,"median":-13.037443,"eighty":-7.964599,"marketCap":1109610787},{"date":"2025-10-31","current":-5.220848,"twenty":-29.877076,"median":-12.972224,"eighty":-7.953979,"marketCap":726014870},{"date":"2025-11-07","current":-4.834251,"twenty":-29.711378,"median":-12.571701,"eighty":-7.940226,"marketCap":671834656},{"date":"2025-11-14","current":-4.836142,"twenty":-29.486392,"median":-12.463895,"eighty":-7.907264,"marketCap":674001865},{"date":"2025-11-21","current":-4.651705,"twenty":-29.472811,"median":-12.190608,"eighty":-7.892301,"marketCap":647995362},{"date":"2025-11-28","current":-4.774382,"twenty":-29.380692,"median":-12.104971,"eighty":-7.828344,"marketCap":667500239},{"date":"2025-12-05","current":-4.657865,"twenty":-29.227764,"median":-11.994815,"eighty":-7.810981,"marketCap":652329779},{"date":"2025-12-12","current":-4.541142,"twenty":-29.080477,"median":-11.893501,"eighty":-7.783049,"marketCap":637159319},{"date":"2025-12-19","current":-5.069807,"twenty":-28.919756,"median":-11.738095,"eighty":-7.770834,"marketCap":713011619},{"date":"2025-12-24","current":-5.069426,"twenty":-28.859539,"median":-11.497394,"eighty":-7.767751,"marketCap":715178828},{"date":"2026-01-02","current":-6.472608,"twenty":-28.816599,"median":-11.288396,"eighty":-7.764631,"marketCap":916729225},{"date":"2026-01-09","current":-5.037011,"twenty":-28.770407,"median":-11.168953,"eighty":-7.762521,"marketCap":715178828},{"date":"2026-01-16","current":-5.324979,"twenty":-28.740036,"median":-11.052278,"eighty":-7.753492,"marketCap":758522999},{"date":"2026-01-23","current":-5.710814,"twenty":-28.694661,"median":-11.004065,"eighty":-7.744705,"marketCap":812703213},{"date":"2026-01-30","current":-5.381635,"twenty":-28.659774,"median":-10.895585,"eighty":-7.288221,"marketCap":769359042},{"date":"2026-02-06","current":-5.594838,"twenty":-28.65347,"median":-10.858762,"eighty":-5.701677,"marketCap":801867170}],"updateTime":1770446553505},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02563\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1194401477","title":"Beijing Biostar Pharmaceuticals (2563) Receives CSRC Filing Notice for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1194401477","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194401477?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:21","pubTimestamp":1770391303,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (2563) announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC), dated 5 February 2026, confirming completion of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"1189658924","title":"BIOSTAR PHARM-B Receives CSRC Filing Notice for Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1189658924","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189658924?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:52","pubTimestamp":1770389534,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) has announced that the company received a filing notice from the China Securities Regulatory Commission (CSRC) dated February 5, 2026. According to the notice, the company has...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","02563","BK1515","BK1574","159938"],"gpt_icon":0},{"id":"1187008784","title":"Beijing Biostar Pharmaceuticals (02563) Announces January 2026 Registered Share Capital Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1187008784","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187008784?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:07","pubTimestamp":1770196021,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (stock code: 02563) released its monthly return for equity issuer for the period ended 31 January 2026. The company, incorporated in the People’s Republic of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"1108309207","title":"BIOSTAR PHARM-B (02563): First Patient Dosed in U.S. Pivotal Clinical Study of Utidelone for Breast Cancer Brain Metastasis","url":"https://stock-news.laohu8.com/highlight/detail?id=1108309207","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108309207?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:37","pubTimestamp":1765978642,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) announced that its wholly-owned U.S. subsidiary, Biostar Pharma, Inc. (US-Biostar), has completed the first patient dosing in a key overseas clinical study: the U.S. pivotal...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","02563","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2591418670","title":"Biostar Pharma Doses First Patient in Pivotal US Trial of Utidelone for HER2-Negative Breast Cancer Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2591418670","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591418670?lang=en_us&edition=fundamental","pubTime":"2025-12-16 12:56","pubTimestamp":1765860991,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals Co. Ltd. announced the dosing of the first patient in a pivotal U.S. clinical trial  evaluating Utidelone Injection  in combination with capecitabine for the treatment of HER2-negative breast cancer brain metastases . The study, involving approximately 120 subjects across nearly 20 clinical centers in the United States, uses a two-stage design with the primary endpoint of central nervous system objective response rate . Previous clinical results with utidelone in combination therapies for HER2-negative BCBM have been presented, including a Phase II study reported at the 2025 ASCO Annual Meeting and another published in JAMA Oncology in 2025, demonstrating CNS-ORR rates of 67.6% and 42.6%, respectively. The U.S. FDA has granted Utidelone orphan drug designation for the treatment of breast cancer brain metastases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLxQ0fp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563","BK1161"],"gpt_icon":0},{"id":"2591704916","title":"Breaking the \"Untreatable\": Biostar Pharma's Utd1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2591704916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591704916?lang=en_us&edition=fundamental","pubTime":"2025-12-16 12:56","pubTimestamp":1765860976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA5037P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02563"],"gpt_icon":0},{"id":"1180194174","title":"BIOSTAR PHARM-B (02563): Court Approves Company's Application to Appoint Receiver for Sub-Fund; Company Contacts Receiver to Advance Process","url":"https://stock-news.laohu8.com/highlight/detail?id=1180194174","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180194174?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:58","pubTimestamp":1765465094,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) announced that the Grand Court of the Cayman Islands (Financial Services Division) ruled on December 3, 2025, approving the company's application to appoint a receiver for the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","09939","159938","02563"],"gpt_icon":0},{"id":"1182113601","title":"Beijing Biostar Pharmaceuticals (02563) Announces November 2025 Monthly Return on Securities Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1182113601","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182113601?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:45","pubTimestamp":1764769515,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 02563) released its monthly return for the period ended 30 November 2025. The company’s total registered share capital remains RMB 364,588,000,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"1123481973","title":"BIOSTAR PHARM-B (02563): Legal Counsel Issues Statutory Demand for Debt Repayment to LFM Oversea Investment Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=1123481973","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123481973?lang=en_us&edition=fundamental","pubTime":"2025-12-01 08:18","pubTimestamp":1764548302,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) announced that as of the date of this announcement, its wholly-owned subsidiary, Biostar Pharma, Inc. (US-Biostar), subscribed to $5 million in the LFM Stable Income Fund SP,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09939","BK1515","BK1161","02563","159938"],"gpt_icon":0},{"id":"1192385621","title":"Beijing Biostar Pharmaceuticals (2563) Issues Supplemental Announcement for 2024 Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1192385621","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192385621?lang=en_us&edition=fundamental","pubTime":"2025-11-28 21:06","pubTimestamp":1764335212,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals (2563) released a supplemental announcement related to its 2024 Annual Report, published on 24 July 2025. This update focuses on the company’s employee incentive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"1172737033","title":"Beijing Biostar Pharmaceuticals (02563) Publishes Monthly Return for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1172737033","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172737033?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:01","pubTimestamp":1762167674,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (02563) submitted its Monthly Return on Movements in Securities for the period ended 31 October 2025. The company reported that its total registered share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"1109626394","title":"HK Stock Movement | BIOSTAR PHARM-B (02563) Plunges Over 37% as Major Share Unlock Hits Post One-Year Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1109626394","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109626394?lang=en_us&edition=fundamental","pubTime":"2025-10-31 11:00","pubTimestamp":1761879635,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) saw its shares plummet more than 37% intraday. At press time, the stock was down 29.98% to HK$3.55, with a turnover of HK$5.82 million. The sharp decline followed the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1574","BK1515","BK1161","02563","09939"],"gpt_icon":0},{"id":"1176635985","title":"BIOSTAR PHARM-B (02563) Shareholders Deposit Shares with Huatai Hong Kong Worth HK$125 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1176635985","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176635985?lang=en_us&edition=fundamental","pubTime":"2025-10-15 08:30","pubTimestamp":1760488225,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on October 14th, shareholders of BIOSTAR PHARM-B (02563) deposited shares with Huatai Hong Kong, with a custody market value of HK$125...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","02563","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2570522013","title":"FDA Grants Orphan Drug Designation to Biostar Pharma’s Utidelone for Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2570522013","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570522013?lang=en_us&edition=fundamental","pubTime":"2025-09-25 21:38","pubTimestamp":1758807539,"startTime":"0","endTime":"0","summary":"**Biostar Pharma's Utidelone Receives FDA Orphan Drug Designation for Pancreatic Cancer** SAN FRANCISCO, Sept. 25, 2025 - Biostar Pharma, Inc., a wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd., has announced that its core pipeline product, Utidelone, has been granted Orphan Drug Designation  by the U.S. Food and Drug Administration  for the treatment of pancreatic cancer. This marks the third ODD for Utidelone, following previous designations for breast cancer brain metastases and gastric cancer. The FDA's decision is based on promising preclinical and early clinical results, including a Phase II study showing an objective response rate of 27.27% and a disease control rate of 72.72% in advanced, unresectable pancreatic cancer. No other organizations were named as recipients of this regulatory designation. Pancreatic cancer remains one of the most challenging malignancies to treat, with a five-year survival rate of just 10%. Utidelone's new designation highlights","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL5Txcxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02563"],"gpt_icon":0},{"id":"2567119284","title":"Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119284?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:01","pubTimestamp":1757937696,"startTime":"0","endTime":"0","summary":"Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule . The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL7sPw5y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563","BK1161"],"gpt_icon":0},{"id":"2567119279","title":"Biostar Pharma Successively Achieved First Patient Dosing for Two Phase Ii/Iii Multiregional Clinical Trials of Utidelone Capsule (Utd2)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119279?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:00","pubTimestamp":1757937612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUA92THRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02563"],"gpt_icon":0},{"id":"1178879979","title":"BIOSTAR PHARM-B (02563) Reports Interim Results with Net Loss of RMB 54.04 Million, Narrowing 23.41% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1178879979","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178879979?lang=en_us&edition=fundamental","pubTime":"2025-08-28 19:17","pubTimestamp":1756379845,"startTime":"0","endTime":"0","summary":"BIOSTAR PHARM-B (02563) announced its interim results for the six months ended June 30, 2025. The company reported revenue of RMB 14.787 million, representing a decrease of 55.36% compared to the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02563","159938","BK1515","09939"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}